Here are five notes.
1. This is the second expanded indication in a little over two years.
2. The new approved indications are: use in OLIF 51 procedures with Divergence-L Interbody Fusion Device at a single level from L5-S1; use in OLIF 25 procedures with Pivox Oblique Lateral Spine System at a single level from L2-L5; and use in ALIF procedures with Divergence-L Interbody Fusion Device at a single level from L2-S1.
3. Infuse Bone Graft is used with certain Medtronic interbody fusion devices to treat lumbar degenerative disc disease, which can cause back and/or leg pain, tingling or numbness in the legs or buttocks, or difficulty walking.
4. On the market since 2002, Infuse Bone Graft is approved for certain spine, oral-maxillofacial and orthopedic trauma surgeries.
5. A manufactured version of a body’s protein that promotes new bone growth called rhBMP-2 is the active ingredient in Infuse Bone Graft.
More articles on supply chain:
Acclarent launches 3-D navigation system for ENT procedures — 4 insights
McKesson board names new director: 4 key points
Takeda nearing agreement to buy Shire for $60B — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.